Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu-Hung Wang

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Blood Advances|October 6, 2021
A CIBERSORTx-based immune cell scoring system could independently predict the prognosis of patients with myelodysplastic syndromesYu-Hung Wang, Hsin-An Hou, Chien-Chin Lin, et al.
Leukemia|November 3, 2023
Higher MDMX expression was associated with hypomethylating agent resistance and inferior survival in MDS patients, inferring it a potential therapeutic targetYu-Hung Wang, Chien-Chin Lin, Kristian Gurashi, et al.
Cell Reports. Medicine|February 1, 2025
An integrative multiparametric approach stratifies putative distinct phenotypes of blast phase chronic myelomonocytic leukemiaKristian Gurashi, Yu-Hung Wang, Fabio M R Amaral, et al.
British Journal of Haematology|December 31, 2024
HOPX as a tumour-suppressive protein in T-cell acute lymphoblastic leukaemiaChien-Chin Lin, Chia-Lang Hsu, Chi-Yuan Yao, et al.
Cancer Science|April 28, 2026
An Immune Dysfunction Signature Score Predicts Survival in MDS Patients: Insights From a Longitudinal, Multicenter StudyYu-Hung Wang, Carmelo Gurnari, Valeria Visconte, et al.
British Journal of Haematology|February 6, 2023
A three-gene leukaemic stem cell signature score is robustly prognostic in chronic myelomonocytic leukaemiaYu-Hung Wang, Chi-Yuan Yao, Chien-Chin Lin, et al.
Blood Cancer Journal|October 13, 2020
ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burdenYu-Hung Wang, Chien-Chin Lin, Sze-Hwei Lee, et al.
British Journal of Haematology|May 22, 2025
Heterogeneity in outcomes of TP53-mutated myeloproliferative neoplasms based on disease phenotype and mutational statusTalha Badar, James M Foran, Jan Philipp Bewersdorf, et al.
Ejhaem|August 19, 2024
IDH2 mutation accelerates TPO-induced myelofibrosis with enhanced S100a8/a9 and NFκB signaling in vivoChien-Chin Lin, Chi-Yuan Yao, Yu-Hung Wang, et al.
Hematological Oncology|November 24, 2022
Distinct genetic landscapes and their clinical implications in younger and older patients with myelodysplastic syndromesWan-Hsuan Lee, Chien-Chin Lin, Yu-Hung Wang, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Blood Advances|October 6, 2021
A CIBERSORTx-based immune cell scoring system could independently predict the prognosis of patients with myelodysplastic syndromesYu-Hung Wang, Hsin-An Hou, Chien-Chin Lin, et al.
Leukemia|November 3, 2023
Higher MDMX expression was associated with hypomethylating agent resistance and inferior survival in MDS patients, inferring it a potential therapeutic targetYu-Hung Wang, Chien-Chin Lin, Kristian Gurashi, et al.
Cell Reports. Medicine|February 1, 2025
An integrative multiparametric approach stratifies putative distinct phenotypes of blast phase chronic myelomonocytic leukemiaKristian Gurashi, Yu-Hung Wang, Fabio M R Amaral, et al.
British Journal of Haematology|December 31, 2024
HOPX as a tumour-suppressive protein in T-cell acute lymphoblastic leukaemiaChien-Chin Lin, Chia-Lang Hsu, Chi-Yuan Yao, et al.
Cancer Science|April 28, 2026
An Immune Dysfunction Signature Score Predicts Survival in MDS Patients: Insights From a Longitudinal, Multicenter StudyYu-Hung Wang, Carmelo Gurnari, Valeria Visconte, et al.
British Journal of Haematology|February 6, 2023
A three-gene leukaemic stem cell signature score is robustly prognostic in chronic myelomonocytic leukaemiaYu-Hung Wang, Chi-Yuan Yao, Chien-Chin Lin, et al.
Blood Cancer Journal|October 13, 2020
ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burdenYu-Hung Wang, Chien-Chin Lin, Sze-Hwei Lee, et al.
British Journal of Haematology|May 22, 2025
Heterogeneity in outcomes of TP53-mutated myeloproliferative neoplasms based on disease phenotype and mutational statusTalha Badar, James M Foran, Jan Philipp Bewersdorf, et al.
Ejhaem|August 19, 2024
IDH2 mutation accelerates TPO-induced myelofibrosis with enhanced S100a8/a9 and NFκB signaling in vivoChien-Chin Lin, Chi-Yuan Yao, Yu-Hung Wang, et al.
Hematological Oncology|November 24, 2022
Distinct genetic landscapes and their clinical implications in younger and older patients with myelodysplastic syndromesWan-Hsuan Lee, Chien-Chin Lin, Yu-Hung Wang, et al.
Pageof 4